Cutaneous adverse events during vemurafenib therapy

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Vemurafenib is a targeted oral therapy for BRAF V600E-mutated stage IV melanoma.
• Cutaneous adverse events associated with vemurafenib range from benign rashes to malignant conditions like keratoacanthoma and squamous cell carcinoma.

Purpose of the Study:

• To review clinical data on the frequency and severity of dermatologic side effects of vemurafenib.
• To characterize vemurafenib-induced adverse events using case series and noncontrolled studies.

Main Methods:

• Review of clinical data on vemurafenib's dermatologic side effects.
• Analysis of case series and noncontrolled studies on vemurafenib safety.

Main Results:

• Benign vemurafenib-induced skin side effects are typically not severe or life-threatening.
• Management of benign side effects often involves dose interruptions, reductions, or topical therapies.
• Malignant lesions such as squamous cell carcinomas and keratoacanthomas are effectively treated by simple excision without vemurafenib discontinuation.

Conclusions:

• Awareness and routine dermatologic assessment are crucial for managing vemurafenib's adverse events.
• Timely management allows for optimal therapeutic benefit in patients receiving vemurafenib.
• Vemurafenib therapy can be safely continued even when managing associated skin cancers.